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To the Editor: We read with interest the paper by Maruyama
et al.1 recently published in Kidney International. The authors
report that the level of CD34þ cell count was an
independent predictor of cardiovascular events in patients
on chronic hemodialysis. Although this result is consistent
with the hypothetical role of CD34þ cells in cardiovascular
homeostasis and is in line with earlier literature,2,3 there are
several potential pitfalls in this study that require attention.
Most important, the CD34þ cell count was expressed per
unit of volume (ml), thus being artificially affected by
hemodilution and hemoconcentration, which are extremely
common in hemodialysis patients. Thus, as CD34þ cells
belong to the white blood cell population, low CD34þ cell
count could simply reflect a lower white blood cell count due
to hemodilution. The observation that the correlation
between the CD34þ cell count and white blood cell count
was the strongest and an independent one (Table 1 of the
paper) strongly supports this explanation. That hemodilution
predicts outcomes in hemodialysis patients would not be
surprising. To avoid this artefact, the CD34þ cell count
should be always expressed as a fraction of the number of
events acquired in flow cytometry analyses.4 This is of
paramount importance in patients subjected to day-to-day
changes in body fluids. In addition, the authors failed to
report critical details on the methods for CD34þ cell
enumeration, such as antibody clones, fluorochromes, and
the number of acquired events.4 Altogether, these limitations
make results of the study by Maruyama et al. poorly
reproducible.
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We thank Dr Fadini et al.1 for their interest
in our recently published article, showing that a reduced
number of circulating CD34þ cells predicts both future
cardiovascular events and all-cause deaths in chronic
hemodialysis patients.
They raised the point that we expressed the CD34þ cell
count as per unit of blood volume. In most earlier studies,
the number of endothelial progenitor cells or CD34þ cells
has been expressed as a ratio to the number of mono-
nuclear cells.2,3 In contrast, we measured the actual
number of CD34þ cells and expressed them as per
microliter. Our hypothesis was that the circulating
endothelial progenitor cells contribute to the maintenance
of the vascular endothelium. Therefore, we assumed that
the actual number, not the ratio, of circulating CD34þ
cells would be of primary importance. In our earlier
studies, we have shown successfully that the actual number
of circulating CD34þ cells was related to various clinical
factors of non-dialysis patients.4–8
Dr Fadini et al. expressed special concern about
hemodilution and hemoconcentration in hemodialysis
patients. They wondered whether a low CD34þ cell count
could reflect simply a low white blood cell count because of
hemodilution. It is true that the levels of various factors
including albumin, hemoglobuin, white blood cell count,
and CD34þ cell count are influenced by the fluid status.
However, in our study, the Cox analysis showed that the
levels of albumin and CD34þ cell count, but not the levels
of hemoglobuin or WBC count, were independent
predictors of prognosis for hemodialysis patients.
Concerning the methodology, not all the information
was described in our paper because of space constraints.
Instead, we quoted our article which details the precise
method to obtain an accurate number of CD34þ cells.9
One of the advantages of this method is in fact its
reproducibility, as described in our papers.9,10
In summary, although it remains to be determined
whether it is the ratio or the actual number of CD34þ
cells that is the better biomarker, accumulating evidence
suggests that circulating progenitor cells contribute to
cardiovascular homeostasis.
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